1. Clinical & Scientific Overview
Filgrastim (rHuG-CSF) (TIP-MED-000578, Reference Code [ONC-29]) is classified under
Oncology & Antineoplastic Medicines as a Oncology Supportive Care (Myeloid Growth Factor) • Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor (G-CSF).
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Neupogen (Roche / Amgen), Grafeel (Dr. Reddy's Laboratories), Neukine (Intas Pharmaceuticals)
Pre-Filled Syringe / Vial for SC or IV Injection: 300 mcg/0.5 mL, 300 mcg/1 mL
Oncology Specialisation & Cytotoxic Safety Protocol
Oncology Supportive Care (Myeloid Growth Factor)
Oncology Supportive Care / Cytoprotective Adjunct (Not Direct Antineoplastic)
Standard Regimen & Cycle Context: 5 mcg/kg/day Subcutaneously starting AT LEAST 24 HOURS AFTER completion of cytotoxic chemotherapy, continued daily until post-nadir ANC recovers.
Signature Dose-Limiting Toxicities & Organ Monitoring: CRITICAL TIMING RULE: Never administer Filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy (cycling myeloid progenitors are destroyed by chemotherapy, worsening neutropenia!); causes medullary bone pain in 20–30% of patients (treated effectively with paracetamol or oral loratadine 10 mg), splenomegaly/rare splenic rupture, and ARDS when combined with bleomycin.
Extravasation, Premedication & Safe Cytotoxic Handling: Explicitly classified as Oncology Supportive Care (non-cytotoxic); store refrigerated at 2–8°C; start >=24 hours post-chemotherapy and counsel patients on medullary bone pain management.
3. Mechanism of Action & Pharmacodynamics
Binds G-CSF receptors on bone marrow myeloid progenitor cells via JAK/STAT signalling, stimulating proliferation, differentiation, and end-cell functional activation of neutrophils while accelerating marrow release.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and treatment of Febrile Neutropenia in patients receiving myelosuppressive cytotoxic chemotherapy
- Peripheral blood haematopoietic stem cell mobilisation
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 5 mcg/kg/day Subcutaneously starting AT LEAST 24 HOURS AFTER completion of cytotoxic chemotherapy, continued daily until post-nadir ANC recovers.
Administration & Meal Timing: 5 mcg/kg/day Subcutaneously starting AT LEAST 24 HOURS AFTER completion of cytotoxic chemotherapy, continued daily until post-nadir ANC recovers.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Filgrastim or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: CRITICAL TIMING RULE: Never administer Filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy (cycling myeloid progenitors are destroyed by chemotherapy, worsening neutropenia!); causes medullary bone pain in 20–30% of patients (treated effectively with paracetamol or oral loratadine 10 mg), splenomegaly/rare splenic rupture, and ARDS when combined with bleomycin.
8. Adverse Effects Profile
- CRITICAL TIMING RULE: Never administer Filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy (cycling myeloid progenitors are destroyed by chemotherapy, worsening neutropenia!); causes medullary bone pain in 20–30% of patients (treated effectively with paracetamol or oral loratadine 10 mg), splenomegaly/rare splenic rupture, and ARDS when combined with bleomycin.
- CRITICAL TIMING RULE: Never administer Filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy (cycling myeloid progenitors are destroyed by chemotherapy, worsening neutropenia!); causes medullary bone pain in 20–30% of patients (treated effectively with paracetamol or oral loratadine 10 mg), splenomegaly/rare splenic rupture, and ARDS when combined with bleomycin.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL TIMING RULE: Never administer Filgrastim within 24 hours before or 24 hours after cytotoxic chemotherapy (cycling myeloid progenitors are destroyed by chemotherapy, worsening neutropenia!); causes medullary bone pain in 20–30% of patients (treated effectively with paracetamol or oral loratadine 10 mg), splenomegaly/rare splenic rupture, and ARDS when combined with bleomycin.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Explicitly classified as Oncology Supportive Care (non-cytotoxic); store refrigerated at 2–8°C; start >=24 hours post-chemotherapy and counsel patients on medullary bone pain management.
Pharmacist Patient Counselling Points:
- Explicitly classified as Oncology Supportive Care (non-cytotoxic); store refrigerated at 2–8°C; start >=24 hours post-chemotherapy and counsel patients on medullary bone pain management.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Explicitly classified as Oncology Supportive Care (non-cytotoxic); store refrigerated at 2–8°C; start >=24 hours post-chemotherapy and counsel patients on medullary bone pain management.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.